Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Sees Unusually-High Trading Volume – Here’s What Happened

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) saw strong trading volume on Thursday . 107,552 shares traded hands during mid-day trading, a decline of 19% from the previous session’s volume of 132,895 shares.The stock last traded at $9.08 and had previously closed at $9.32.

Analysts Set New Price Targets

SGIOY has been the topic of several research analyst reports. Jefferies Financial Group raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. The Goldman Sachs Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 15th. Finally, Zacks Research upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research report on Monday, May 25th. Two investment analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Shionogi & Co., Ltd. Unsponsored ADR presently has a consensus rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Up 0.2%

The business has a fifty day moving average of $8.96 and a 200 day moving average of $9.62. The stock has a market cap of $15.39 billion, a price-to-earnings ratio of 9.04, a P/E/G ratio of 3.34 and a beta of 0.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.58 and a quick ratio of 1.46.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last posted its earnings results on Monday, August 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.18. The firm had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.47%. On average, equities analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, the company has built its business around drug discovery and has a particular focus on infectious diseases, including antiviral and antibacterial treatments.

Shionogi’s products include Xofluza (baloxavir marboxil), an oral treatment for influenza, and Fetcroja (cefiderocol), an antibiotic used for certain difficult-to-treat bacterial infections.